FDMT

4D Molecular Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-18

Figures on this page computed 2026-11-08 12:48 UTC

Last close

12.28USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-18

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-18
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
-164.4%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
-128.7%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
0.04Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Margins is the furthest below its sector's middle: 0.12 against 0.23 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

4.57x

1.78x

1.63x

1.15x

0.74x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-18

Sales4.57x
Its own average over 9 years, 18.6M.
Profit1.78x
Its own average over 9 years, -78.6M.
Free cash flow1.63x
Its own average over 9 years, -67.1M.
Debt1.15x
Its own average over 5 years, 18.7M.
Price0.74x
Its own average over 7 years, 17. Market data, 2026-11-04

Sales is furthest from its own average, at 4.57 times.

Sales is 4.57 times its own 9-year average; Profit is 1.78 times its own 9-year average; Free cash flow is 1.63 times its own 9-year average; Debt is 1.15 times its own 5-year average; Price is 0.74 times its own 7-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-18

Sales against its own 9-year average4.57
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
The filing itself
Profit against its own 9-year average1.78
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
The filing itself
Free cash flow against its own 9-year average1.63
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
The filing itself
Debt against its own 5-year average1.15
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
The filing itself
Price against its own 7-year average0.74Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD